Long‐term health benefit and economic return of time in range ( TIR ) improvement in individuals with type 2 diabetes
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Khalid Alkhuzam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Cardiovascular Diseases, Health Care Costs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
Time in range (TIR) is an important metric to measure variability of blood glucose levels. The aim is to quantify the long‐term health benefits and economic return associated with improved TIR for individuals with type 2 diabetes (T2D).
Method
A Markov model with three states (T2D, T2D with cardiovascular disease (CVD) and death) estimated 20‐year medical costs, quality‐adjusted life‐years (QALY) gained and CVD risk under four TIR scenarios: >85%, 71%–85%, 51%–70% and ≤50%. The T2D population was identified using the National Health and Nutrition Examination Survey, and model parameters were sourced from literature. Costs were estimated from a healthcare sector perspective and standardized to 2021 US dollars. Cost ceilings were determined using three willingness‐to‐pay (WTP) thresholds: $100 000/QALY, $50 000/QALY and $0/QALY (cost‐saving).
Results
Compared to TIR 85%, a 1.18 QALY increase and 8.75% CVD risk reduction. To be cost‐effective at $100 000/QALY, annual costs for TIR improvements from 85% should be
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Department of Medicine and Pharmacology, School of Medicine, Tulane University, New Orleans, Louisiana, USA.
- Department of Health Policy and Management, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
- Department of Population Health Sciences, Weill Cornell Medical College, New York, New York, USA.
- Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Piaopiao Li, Lizheng Shi, Vivian Fonseca, Hui Shao
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Alkhuzam, K., Li, P., Abuloha, S., Xue, Q., Shi, L., Fonseca, V., Zhang, Y., & Shao, H. (2025). Long‐term health benefit and economic return of time in range ( TIR ) improvement in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16168
Vancouver
Alkhuzam K, Li P, Abuloha S, Xue Q, Shi L, Fonseca V, et al. Long‐term health benefit and economic return of time in range ( TIR ) improvement in individuals with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16168
BibTeX
@article{Alkhuzam2025,
author = {Alkhuzam, Khalid and Li, Piaopiao and Abuloha, Sumaya and Xue, Qiaochu and Shi, Lizheng and Fonseca, Vivian and Zhang, Yongkang and Shao, Hui},
title = {Long‐term health benefit and economic return of time in range ( TIR ) improvement in individuals with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16168}
}
EUVIMED